Loading…
Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis
Liver fibrosis or cirrhosis is associated with the dismal prognosis of hepatocellular carcinoma (HCC), and it might also be involved in intrahepatic cholangiocarcinoma (ICC). The effect of hepatic fibrosis on the survival of ICC patients is still unclear. This study aims to explore whether liver fib...
Saved in:
| Published in: | BMC cancer 2020-06, Vol.20 (1), p.556-556, Article 556 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c628t-9875b2546ed9a15f1ba31ff883c9e602b5ca399c989c7a9b842620fe4a54e2a53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c628t-9875b2546ed9a15f1ba31ff883c9e602b5ca399c989c7a9b842620fe4a54e2a53 |
| container_end_page | 556 |
| container_issue | 1 |
| container_start_page | 556 |
| container_title | BMC cancer |
| container_volume | 20 |
| creator | Zhang, Jian Xi Li, Peipei Chen, Zhibin Lin, Huogui Cai, Zhezhen Liao, Weijia Pan, Zirong |
| description | Liver fibrosis or cirrhosis is associated with the dismal prognosis of hepatocellular carcinoma (HCC), and it might also be involved in intrahepatic cholangiocarcinoma (ICC). The effect of hepatic fibrosis on the survival of ICC patients is still unclear. This study aims to explore whether liver fibrosis impacts the overall survival (OS) and disease-specific survival (DSS) of ICC patients.
Data of 729 eligible ICC patients receiving different therapies from the Surveillance, Epidemiology, and End Results database (2004-2015) were analyzed. Unmatched, propensity score-matched, and propensity score-weighted cohorts were used to investigate the relationships of different fibrosis scores (low fibrosis score vs. high fibrosis score) and survival. A Cox regression and Kaplan-Meier curves were used to explore the influence of fibrosis score on patients' survival. Stratified analyses based on treatment modality were conducted to compare the survival difference in ICC patients with different fibrosis scores.
Before matching, the one-, three-, and five-year OS were 50.9, 28.0, and 16.1% in the low fibrosis score group (n = 465) and 39.3, 20.1, and 8.0% in the high fibrosis score group (n = 264) (P |
| doi_str_mv | 10.1186/s12885-020-07051-5 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_048c42a39b4f4618a3276958fbded5a5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A627414319</galeid><doaj_id>oai_doaj_org_article_048c42a39b4f4618a3276958fbded5a5</doaj_id><sourcerecordid>A627414319</sourcerecordid><originalsourceid>FETCH-LOGICAL-c628t-9875b2546ed9a15f1ba31ff883c9e602b5ca399c989c7a9b842620fe4a54e2a53</originalsourceid><addsrcrecordid>eNptktuK1TAUhosozjj6Al5IQRC96Jhjm86FMAweNgwIHq7DanbSZtM2NUkH9zv40GYfHHdFetGy-uUL6-fPsucYXWIsyrcBEyF4gQgqUIU4LviD7ByzCheEoerhyfdZ9iSEDUK4Ekg8zs4o4bSuSnGe_VoNE6iYO5P39k773NjGu2BDHpTzOndjPnnXjvsRmJgI5YYhjWOnPUxWh9w4n9sxeuj0BNGqXHWuh7G1ToFXdnQDXOWw80x6DDZuj-4Bours2OYwQr9NFzzNHhnog352fF9k3z-8_3bzqbj9_HF1c31bqJKIWNSi4g3hrNTrGjA3uAGKjRGCqlqXiDRcAa1rVYtaVVA3gpGSIKMZcKYJcHqRrQ7etYONnLwdwG-lAyv3A-dbCT4t0muJmFCMJF3DDCuxAEqqsubCNGu95nvXu4NrmptBr5XeBdEvpMs_o-1k6-5kReqy5FUSvD4KvPsx6xDlYIPSfUpQuzlIwnBahlW0TujLf9CNm30Kb08xQSkl5C_VQlrAjsale9VOKq9LUiWQ4p3r8j9UetZ6sMqN2tg0Xxx4sziQmKh_xhbmEOTq65cl--qE7TT0sQuun6N1Y1iC5ACqVLrgtbkPDiO5K7k8lFymkst9yeUu8henkd8f-dNq-hslM_e2</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2414833322</pqid></control><display><type>article</type><title>Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Zhang, Jian Xi ; Li, Peipei ; Chen, Zhibin ; Lin, Huogui ; Cai, Zhezhen ; Liao, Weijia ; Pan, Zirong</creator><creatorcontrib>Zhang, Jian Xi ; Li, Peipei ; Chen, Zhibin ; Lin, Huogui ; Cai, Zhezhen ; Liao, Weijia ; Pan, Zirong</creatorcontrib><description>Liver fibrosis or cirrhosis is associated with the dismal prognosis of hepatocellular carcinoma (HCC), and it might also be involved in intrahepatic cholangiocarcinoma (ICC). The effect of hepatic fibrosis on the survival of ICC patients is still unclear. This study aims to explore whether liver fibrosis impacts the overall survival (OS) and disease-specific survival (DSS) of ICC patients.
Data of 729 eligible ICC patients receiving different therapies from the Surveillance, Epidemiology, and End Results database (2004-2015) were analyzed. Unmatched, propensity score-matched, and propensity score-weighted cohorts were used to investigate the relationships of different fibrosis scores (low fibrosis score vs. high fibrosis score) and survival. A Cox regression and Kaplan-Meier curves were used to explore the influence of fibrosis score on patients' survival. Stratified analyses based on treatment modality were conducted to compare the survival difference in ICC patients with different fibrosis scores.
Before matching, the one-, three-, and five-year OS were 50.9, 28.0, and 16.1% in the low fibrosis score group (n = 465) and 39.3, 20.1, and 8.0% in the high fibrosis score group (n = 264) (P < 0.001), respectively. After propensity score matching, the one-, three-, and five-year OS were 45.0, 26.0, and 10.2% in the low fibrosis score group and 36.0, 8.1, and 2.3% in the high fibrosis score group (P = 0.008), respectively. The multivariate Cox regression results showed that a high fibrosis score was an independent risk factor of OS. Additionally, patients with high fibrosis scores achieved low DSS after matching (P = 0.032). The survival benefits of the low fibrosis score group were consistent across treatment cohorts.
High fibrosis scores were associated with poor clinical outcomes of ICC patients receiving different common therapies.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-020-07051-5</identifier><identifier>PMID: 32539768</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged ; Analysis ; Bile Duct Neoplasms - complications ; Bile Duct Neoplasms - mortality ; Bile Duct Neoplasms - pathology ; Bile Duct Neoplasms - therapy ; Bile Ducts, Intrahepatic - pathology ; Biliary tract cancer ; Cancer therapies ; Chemotherapy ; Cholangiocarcinoma ; Cholangiocarcinoma - complications ; Cholangiocarcinoma - mortality ; Cholangiocarcinoma - pathology ; Cholangiocarcinoma - therapy ; Cirrhosis ; Epidemiology ; Female ; Fibrosis ; Follow-Up Studies ; Hepatocellular carcinoma ; Humans ; Intrahepatic cholangiocarcinoma ; Kaplan-Meier Estimate ; Liver ; Liver cancer ; Liver cirrhosis ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - etiology ; Liver Cirrhosis - pathology ; Liver fibrosis ; Male ; Medical prognosis ; Medical research ; Metastasis ; Middle Aged ; Patients ; Population ; Prognosis ; Propensity Score ; Regression analysis ; Risk Factors ; SEER Program - statistics & numerical data ; Severity of Illness Index ; Statistical analysis ; Surgery ; Survival ; Survival analysis ; Treatment Outcome ; Tumors</subject><ispartof>BMC cancer, 2020-06, Vol.20 (1), p.556-556, Article 556</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c628t-9875b2546ed9a15f1ba31ff883c9e602b5ca399c989c7a9b842620fe4a54e2a53</citedby><cites>FETCH-LOGICAL-c628t-9875b2546ed9a15f1ba31ff883c9e602b5ca399c989c7a9b842620fe4a54e2a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296657/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2414833322?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32539768$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Jian Xi</creatorcontrib><creatorcontrib>Li, Peipei</creatorcontrib><creatorcontrib>Chen, Zhibin</creatorcontrib><creatorcontrib>Lin, Huogui</creatorcontrib><creatorcontrib>Cai, Zhezhen</creatorcontrib><creatorcontrib>Liao, Weijia</creatorcontrib><creatorcontrib>Pan, Zirong</creatorcontrib><title>Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Liver fibrosis or cirrhosis is associated with the dismal prognosis of hepatocellular carcinoma (HCC), and it might also be involved in intrahepatic cholangiocarcinoma (ICC). The effect of hepatic fibrosis on the survival of ICC patients is still unclear. This study aims to explore whether liver fibrosis impacts the overall survival (OS) and disease-specific survival (DSS) of ICC patients.
Data of 729 eligible ICC patients receiving different therapies from the Surveillance, Epidemiology, and End Results database (2004-2015) were analyzed. Unmatched, propensity score-matched, and propensity score-weighted cohorts were used to investigate the relationships of different fibrosis scores (low fibrosis score vs. high fibrosis score) and survival. A Cox regression and Kaplan-Meier curves were used to explore the influence of fibrosis score on patients' survival. Stratified analyses based on treatment modality were conducted to compare the survival difference in ICC patients with different fibrosis scores.
Before matching, the one-, three-, and five-year OS were 50.9, 28.0, and 16.1% in the low fibrosis score group (n = 465) and 39.3, 20.1, and 8.0% in the high fibrosis score group (n = 264) (P < 0.001), respectively. After propensity score matching, the one-, three-, and five-year OS were 45.0, 26.0, and 10.2% in the low fibrosis score group and 36.0, 8.1, and 2.3% in the high fibrosis score group (P = 0.008), respectively. The multivariate Cox regression results showed that a high fibrosis score was an independent risk factor of OS. Additionally, patients with high fibrosis scores achieved low DSS after matching (P = 0.032). The survival benefits of the low fibrosis score group were consistent across treatment cohorts.
High fibrosis scores were associated with poor clinical outcomes of ICC patients receiving different common therapies.</description><subject>Aged</subject><subject>Analysis</subject><subject>Bile Duct Neoplasms - complications</subject><subject>Bile Duct Neoplasms - mortality</subject><subject>Bile Duct Neoplasms - pathology</subject><subject>Bile Duct Neoplasms - therapy</subject><subject>Bile Ducts, Intrahepatic - pathology</subject><subject>Biliary tract cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Cholangiocarcinoma</subject><subject>Cholangiocarcinoma - complications</subject><subject>Cholangiocarcinoma - mortality</subject><subject>Cholangiocarcinoma - pathology</subject><subject>Cholangiocarcinoma - therapy</subject><subject>Cirrhosis</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Follow-Up Studies</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Intrahepatic cholangiocarcinoma</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver fibrosis</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Population</subject><subject>Prognosis</subject><subject>Propensity Score</subject><subject>Regression analysis</subject><subject>Risk Factors</subject><subject>SEER Program - statistics & numerical data</subject><subject>Severity of Illness Index</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptktuK1TAUhosozjj6Al5IQRC96Jhjm86FMAweNgwIHq7DanbSZtM2NUkH9zv40GYfHHdFetGy-uUL6-fPsucYXWIsyrcBEyF4gQgqUIU4LviD7ByzCheEoerhyfdZ9iSEDUK4Ekg8zs4o4bSuSnGe_VoNE6iYO5P39k773NjGu2BDHpTzOndjPnnXjvsRmJgI5YYhjWOnPUxWh9w4n9sxeuj0BNGqXHWuh7G1ToFXdnQDXOWw80x6DDZuj-4Bours2OYwQr9NFzzNHhnog352fF9k3z-8_3bzqbj9_HF1c31bqJKIWNSi4g3hrNTrGjA3uAGKjRGCqlqXiDRcAa1rVYtaVVA3gpGSIKMZcKYJcHqRrQ7etYONnLwdwG-lAyv3A-dbCT4t0muJmFCMJF3DDCuxAEqqsubCNGu95nvXu4NrmptBr5XeBdEvpMs_o-1k6-5kReqy5FUSvD4KvPsx6xDlYIPSfUpQuzlIwnBahlW0TujLf9CNm30Kb08xQSkl5C_VQlrAjsale9VOKq9LUiWQ4p3r8j9UetZ6sMqN2tg0Xxx4sziQmKh_xhbmEOTq65cl--qE7TT0sQuun6N1Y1iC5ACqVLrgtbkPDiO5K7k8lFymkst9yeUu8henkd8f-dNq-hslM_e2</recordid><startdate>20200615</startdate><enddate>20200615</enddate><creator>Zhang, Jian Xi</creator><creator>Li, Peipei</creator><creator>Chen, Zhibin</creator><creator>Lin, Huogui</creator><creator>Cai, Zhezhen</creator><creator>Liao, Weijia</creator><creator>Pan, Zirong</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200615</creationdate><title>Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis</title><author>Zhang, Jian Xi ; Li, Peipei ; Chen, Zhibin ; Lin, Huogui ; Cai, Zhezhen ; Liao, Weijia ; Pan, Zirong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c628t-9875b2546ed9a15f1ba31ff883c9e602b5ca399c989c7a9b842620fe4a54e2a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Analysis</topic><topic>Bile Duct Neoplasms - complications</topic><topic>Bile Duct Neoplasms - mortality</topic><topic>Bile Duct Neoplasms - pathology</topic><topic>Bile Duct Neoplasms - therapy</topic><topic>Bile Ducts, Intrahepatic - pathology</topic><topic>Biliary tract cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Cholangiocarcinoma</topic><topic>Cholangiocarcinoma - complications</topic><topic>Cholangiocarcinoma - mortality</topic><topic>Cholangiocarcinoma - pathology</topic><topic>Cholangiocarcinoma - therapy</topic><topic>Cirrhosis</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Follow-Up Studies</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Intrahepatic cholangiocarcinoma</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver fibrosis</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Population</topic><topic>Prognosis</topic><topic>Propensity Score</topic><topic>Regression analysis</topic><topic>Risk Factors</topic><topic>SEER Program - statistics & numerical data</topic><topic>Severity of Illness Index</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Jian Xi</creatorcontrib><creatorcontrib>Li, Peipei</creatorcontrib><creatorcontrib>Chen, Zhibin</creatorcontrib><creatorcontrib>Lin, Huogui</creatorcontrib><creatorcontrib>Cai, Zhezhen</creatorcontrib><creatorcontrib>Liao, Weijia</creatorcontrib><creatorcontrib>Pan, Zirong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Jian Xi</au><au>Li, Peipei</au><au>Chen, Zhibin</au><au>Lin, Huogui</au><au>Cai, Zhezhen</au><au>Liao, Weijia</au><au>Pan, Zirong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2020-06-15</date><risdate>2020</risdate><volume>20</volume><issue>1</issue><spage>556</spage><epage>556</epage><pages>556-556</pages><artnum>556</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Liver fibrosis or cirrhosis is associated with the dismal prognosis of hepatocellular carcinoma (HCC), and it might also be involved in intrahepatic cholangiocarcinoma (ICC). The effect of hepatic fibrosis on the survival of ICC patients is still unclear. This study aims to explore whether liver fibrosis impacts the overall survival (OS) and disease-specific survival (DSS) of ICC patients.
Data of 729 eligible ICC patients receiving different therapies from the Surveillance, Epidemiology, and End Results database (2004-2015) were analyzed. Unmatched, propensity score-matched, and propensity score-weighted cohorts were used to investigate the relationships of different fibrosis scores (low fibrosis score vs. high fibrosis score) and survival. A Cox regression and Kaplan-Meier curves were used to explore the influence of fibrosis score on patients' survival. Stratified analyses based on treatment modality were conducted to compare the survival difference in ICC patients with different fibrosis scores.
Before matching, the one-, three-, and five-year OS were 50.9, 28.0, and 16.1% in the low fibrosis score group (n = 465) and 39.3, 20.1, and 8.0% in the high fibrosis score group (n = 264) (P < 0.001), respectively. After propensity score matching, the one-, three-, and five-year OS were 45.0, 26.0, and 10.2% in the low fibrosis score group and 36.0, 8.1, and 2.3% in the high fibrosis score group (P = 0.008), respectively. The multivariate Cox regression results showed that a high fibrosis score was an independent risk factor of OS. Additionally, patients with high fibrosis scores achieved low DSS after matching (P = 0.032). The survival benefits of the low fibrosis score group were consistent across treatment cohorts.
High fibrosis scores were associated with poor clinical outcomes of ICC patients receiving different common therapies.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>32539768</pmid><doi>10.1186/s12885-020-07051-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2407 |
| ispartof | BMC cancer, 2020-06, Vol.20 (1), p.556-556, Article 556 |
| issn | 1471-2407 1471-2407 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_048c42a39b4f4618a3276958fbded5a5 |
| source | Publicly Available Content Database; PubMed Central |
| subjects | Aged Analysis Bile Duct Neoplasms - complications Bile Duct Neoplasms - mortality Bile Duct Neoplasms - pathology Bile Duct Neoplasms - therapy Bile Ducts, Intrahepatic - pathology Biliary tract cancer Cancer therapies Chemotherapy Cholangiocarcinoma Cholangiocarcinoma - complications Cholangiocarcinoma - mortality Cholangiocarcinoma - pathology Cholangiocarcinoma - therapy Cirrhosis Epidemiology Female Fibrosis Follow-Up Studies Hepatocellular carcinoma Humans Intrahepatic cholangiocarcinoma Kaplan-Meier Estimate Liver Liver cancer Liver cirrhosis Liver Cirrhosis - diagnosis Liver Cirrhosis - etiology Liver Cirrhosis - pathology Liver fibrosis Male Medical prognosis Medical research Metastasis Middle Aged Patients Population Prognosis Propensity Score Regression analysis Risk Factors SEER Program - statistics & numerical data Severity of Illness Index Statistical analysis Surgery Survival Survival analysis Treatment Outcome Tumors |
| title | Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T21%3A28%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20liver%20fibrosis%20score%20on%20prognosis%20after%20common%20therapies%20for%20intrahepatic%20cholangiocarcinoma:%20a%20propensity%20score%20matching%20analysis&rft.jtitle=BMC%20cancer&rft.au=Zhang,%20Jian%20Xi&rft.date=2020-06-15&rft.volume=20&rft.issue=1&rft.spage=556&rft.epage=556&rft.pages=556-556&rft.artnum=556&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-020-07051-5&rft_dat=%3Cgale_doaj_%3EA627414319%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c628t-9875b2546ed9a15f1ba31ff883c9e602b5ca399c989c7a9b842620fe4a54e2a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2414833322&rft_id=info:pmid/32539768&rft_galeid=A627414319&rfr_iscdi=true |